Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Debt (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Debt for 3 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • Quarterly Total Debt rose 1.97% to $9.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 million through Dec 2025, up 1.97% year-over-year, with the annual reading at $9.7 million for FY2025, 1.97% up from the prior year.
  • Total Debt for Q4 2025 was $9.7 million at Kura Oncology, roughly flat from $9.7 million in the prior quarter.
  • The five-year high for Total Debt was $9.7 million in Q4 2025, with the low at $9.2 million in Q1 2023.
  • Average Total Debt over 3 years is $9.5 million, with a median of $9.4 million recorded in 2024.
  • The sharpest move saw Total Debt increased 1.91% in 2024, then rose 2.12% in 2025.
  • Over 3 years, Total Debt stood at $9.3 million in 2023, then rose by 2.05% to $9.5 million in 2024, then grew by 1.97% to $9.7 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $9.7 million, $9.7 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.